{"id":3312,"date":"2018-10-04T12:37:11","date_gmt":"2018-10-04T07:07:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3312"},"modified":"2021-07-24T12:57:05","modified_gmt":"2021-07-24T07:27:05","slug":"the-business-cocktails-3","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3","title":{"rendered":"Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner"},"content":{"rendered":"

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million<\/strong><\/p>\n

Hologic<\/strong>, a global champion of women’s health based in Massachusetts, United States, is taking possession of Focal Therapeutics<\/strong>, a medical device company, for USD 125 million<\/strong> to complement its breast-conserving surgery permit<\/strong>. This leads to Focal\u2019s BioZorb<\/strong> implantable used in lumpectomies to designate tumour removal sites for monitoring and future treatments. The device\u2019s titanium marker clips work with existing screening and imaging methods to help improve outcomes over the long term and it is placed during the tissue removal procedure with a range of sizes.<\/p>\n

Allogene zeroed in at USD 287 Million IPO<\/strong><\/p>\n

CAR-T specialist Allogene<\/strong> is ruminating to raise around USD 287 million<\/strong> from a public listing. This cues a quick return to Wall Street for Arie Belldegrun and David Chang. Allogene launched with USD 300 million<\/strong> in the first-round capital<\/strong> and a suite of CAR-T assets approved from Cellectis<\/strong>, a clinical-stage biopharmaceutical company based in France.<\/p>\n

Gamida, Novartis-backed cell therapy startup registers for IPO<\/strong><\/p>\n

Gamida Cell<\/strong>, a leader in the development of cellular and immune therapeutics based in Israel, has registered to raise USD 69 million<\/strong> in a Nasdaq IPO<\/strong>. The Novartis<\/strong>-backed cell therapy player needs the money for a phase 3 trial<\/strong> of its principal candidate in patients with blood cancers. Gamida is working on Cell therapies, and these are already broadly used in the blood cancers treatment such as acute myeloid leukaemia.<\/a><\/p>\n

Aduro loses imperative partner as J&J exits licensing deals<\/strong><\/p>\n

Johnson & Johnson<\/strong> has aborted a trio of licensing deals with Aduro Biotech<\/strong>, based in the US, affecting a key source of income for the clinical-stage cancer immunotherapy specialist. The drug makers first tied up when J&J’s Janssen<\/strong> unit inked two agreements, which gave it exclusive rights to Aduro’s GVAX<\/strong> vaccine platform for prostate cancer <\/a>and product candidates containing ADU-741<\/strong>. A third deal was signed, giving Janssen exclusive rights to all product candidates containing Aduro’s ADU-214<\/strong>, a similar Listeria strain.<\/p>\n","protected":false},"excerpt":{"rendered":"

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women’s health based in Massachusetts, United States, is taking possession of Focal Therapeutics, a medical device company, for USD 125 million to complement its breast-conserving surgery permit. This leads to Focal\u2019s BioZorb implantable used in lumpectomies to designate […]<\/p>\n","protected":false},"author":1,"featured_media":3157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1927,1929,1066,1930,1928,1922,1921,1926,1920,1923,1007,1924,1919,1925,1918,1728,1657,341,423,498],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-3312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-myeloid-leukaemia","tag-adu-741","tag-aduro-biotech","tag-aduros-adu-214","tag-aduros-gvax","tag-allogene","tag-biozorb","tag-blood-cancers","tag-breast-conserving-surgery","tag-car-t-specialist","tag-cellectis","tag-first-round-capital","tag-focal-therapeutics","tag-gamida-cell","tag-hologic","tag-ipo","tag-janssen","tag-johnson-johnson","tag-novartis","tag-prostate-cancer","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nHologic complements Focal; Allogene zeroed in for IPO<\/title>\n<meta name=\"description\" content=\"Johnson & Johnson has aborted a trio of licensing deals with Aduro Biotech, based in the US, affecting a key source of income for the clinical-stage....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hologic complements Focal; Allogene zeroed in for IPO\" \/>\n<meta property=\"og:description\" content=\"Johnson & Johnson has aborted a trio of licensing deals with Aduro Biotech, based in the US, affecting a key source of income for the clinical-stage....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-04T07:07:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hologic complements Focal; Allogene zeroed in for IPO","description":"Johnson & Johnson has aborted a trio of licensing deals with Aduro Biotech, based in the US, affecting a key source of income for the clinical-stage....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3","og_locale":"en_US","og_type":"article","og_title":"Hologic complements Focal; Allogene zeroed in for IPO","og_description":"Johnson & Johnson has aborted a trio of licensing deals with Aduro Biotech, based in the US, affecting a key source of income for the clinical-stage....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-04T07:07:11+00:00","article_modified_time":"2021-07-24T07:27:05+00:00","og_image":[{"width":620,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3","name":"Hologic complements Focal; Allogene zeroed in for IPO","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","datePublished":"2018-10-04T07:07:11+00:00","dateModified":"2021-07-24T07:27:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Johnson & Johnson has aborted a trio of licensing deals with Aduro Biotech, based in the US, affecting a key source of income for the clinical-stage....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-3#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","width":620,"height":410,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1-300x198.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute myeloid leukaemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ADU-741<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aduro Biotech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aduro's ADU-214<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aduro's GVAX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allogene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioZorb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">blood cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">breast-conserving surgery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T specialist<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cellectis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">first-round capital<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Focal Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gamida Cell<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hologic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Janssen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson & Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute myeloid leukaemia<\/span>","<span class=\"advgb-post-tax-term\">ADU-741<\/span>","<span class=\"advgb-post-tax-term\">Aduro Biotech<\/span>","<span class=\"advgb-post-tax-term\">Aduro's ADU-214<\/span>","<span class=\"advgb-post-tax-term\">Aduro's GVAX<\/span>","<span class=\"advgb-post-tax-term\">Allogene<\/span>","<span class=\"advgb-post-tax-term\">BioZorb<\/span>","<span class=\"advgb-post-tax-term\">blood cancers<\/span>","<span class=\"advgb-post-tax-term\">breast-conserving surgery<\/span>","<span class=\"advgb-post-tax-term\">CAR-T specialist<\/span>","<span class=\"advgb-post-tax-term\">Cellectis<\/span>","<span class=\"advgb-post-tax-term\">first-round capital<\/span>","<span class=\"advgb-post-tax-term\">Focal Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Gamida Cell<\/span>","<span class=\"advgb-post-tax-term\">Hologic<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Janssen<\/span>","<span class=\"advgb-post-tax-term\">Johnson & Johnson<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 4, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 4, 2018 12:37 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3312"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3157"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3312"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3312"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}